Abstract:To the editor: The main side effects of topical imiquimod are dose-dependent application-site reactions.1 Recently, we found a Chinese couple developed vitiligo-like depigmentation lesions and lichen planus with genital warts after treatment with 5% imiquimod cream, respectively. The wife, 36 years old, was diagnosed with genital warts based on acetic acid white test. Numerous warty lesions were located on both sides of the labia minora and majora, perineal, perianal areas and external cervical orifice. One week after CO2 laser treatment, 5% imiquimod cream (AldaraTM, 3M Pharmaceuticals, USA) was applied to the external genital area every other night to prevent recurrence. Six weeks later, the patient noticed a few spots of slight hypopigmentation at the imiquimod-applied areas and then stopped using the imiquimod cream. But the hypopigmentation gradually became worse and spread to the perineum and perianal areas. Three months later complete depigmentation occurred on the perineum and perianal skin (Figure 1A). Pigment loss in pubic hairs in the imiquimod-applied areas was also visible. The lesions showed clear demarcation lines and did not extend to the areas that had not been treated with imiquimod. The patient had no personal or family history of vitiligo. She was diagnosed with localized vitiligo.Figure 1.: The clinical manifestation and pathologic findings of the two patients. A: Depigmentation occurred on the perineum and perianal skin of the wife after topical application of imiquimod. B: Gross views of lichen planus lesions of the husband before PDT treatment. C: Histopathological examination of lichen planus lesion on the foreskin of the husband (Original magnification ×100). D: Repigmentation in the vulva, perineum and perianal areas of the wife two months after the completion of 4-month treatment with 0.1% Tacrolimus ointment. E: Fluorescence images after topical application of ALA in the husband. F: Gross views of lesions of the husband after PDT treatment.The husband, 37 years old, was also diagnosed with genital warts distributed in the coronal and foreskin areas. One week after the completion of two-session of CO2 laser treatment, 5% imiquimod cream was applied in the same way as his wife for 3 months. One month later, the patient noticed some papular lesions in the imiquimod-applied areas. Three months later, dermatological examination revealed multiple purple-red specks (Figure 1B). The patient denied any trauma or history of drug allergy. Histopathological examination revealed hyperkeratosis of the epidermis, focal and wedge-type thickening of granular layer, irregular thickening of the cell layer, liquefied degeneration of basal cells, and lymphocyte infiltration in the upper dermis (Figure 1C). He was diagnosed with lichen planus. The wife with localized vitiligo was treated by topical application of 0.1% Tacrolimus ointment twice daily. After 4 months, >70% repigmentation in the vulva, perineum and perianal areas was achieved (Figure 1D). The husband with lichen planus was treated by topical photodynamic therapy (PDT) with 20% 5-Aminolevulinc acid (ALA) cream and a 635 nm diode laser (100 J/cm2, 100 mW/cm2), once a week for 5 weeks till the complete remission was achieved. Figure 1E and 1F shows fluorescence images of lesions before PDT and gross views after PDT treatment. The mode of action of imiquimod involves both natural immune responses and cell-mediated immune responses. Topical application of imiquimod can affect Toll-like receptors, activate immune cells, induce Th1 responses, and ultimately activate cytotoxic T cells, which is useful for the treatment of certain diseases, but can also induce inflammatory skin diseases.2

Imiquimod immunotherapy and ALA photodynamic therapy combination for the treatment of genital bowenoid papulosis

Combination of immunotherapy and photodynamic therapy in the treatment of Bowenoid papulosis

Retrospective Study of Four Treatment Modalities for Bowenoid Papulosis

Topical 5-Aminolevulinic Acid - Photodynamic Therapy for Bowenoid Papulosis

The Combination of Holmium Laser and ALA-PDT for Bowenoid Papulosis with Diffuse Large B-cell Lymphoma.

Photodynamic Therapy of Bowen's Disease Using 5-Aminolevulinic Acid

Therapeutic effect of Imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma

Efficacy and Safety of Photodynamic Therapy on Cutaneous Bowen Disease:A Systematic Review

Ulceration occurring after ALA-PDT combined with plum-blossom needle percussion for the treatment of pretibial Bowen's disease: A case report

Evaluation of Photodynamic Therapy of Skin Cancers with Partial Differential Alpha-Aminolevulinic Acid.

Combination of photodynamic therapy and immunotherapy - evolving role in dermatology

Imiquimod-induced Localized Vitiligo in Wife and Lichen Planus in Husband.

Enhancement of Photodynamic Therapy for Bowen's Disease Using Plum-Blossom Needling to Augment Drug Delivery.

Topical 5-Aminolevulinic Acid Photodynamic Therapy for the Treatment of Condyloma Acuminatum: a Multicenter, Randomized, CO2 Laser-Controlled Trial

Simple Shaving Combined with Photodynamic Therapy for Refractory Bowen Disease

Therapeutic effects of topical photodynamic therapy with 5-aminolevulinic acid on cervical high-grade squamous intraepithelial lesions

Treatment of HPV Infection‐Associated Cervical Condylomata Acuminata with 5‐aminolevulinic Acid‐Mediated Photodynamic Therapy†

Topical 5-aminolevulinic acid photodynamic therapy for laryngeal papillomatosistosis treatment

Real-world Data of 5-Aminolaevulinic Acid-Mediated Photodynamic Therapy for Bowen Disease: a 10-Year Retrospective Study in Patients with Darker-Coloured Skin (2011-2021).

A Case Series Pilot Study on the Combination of 5-Aminolevulinic Acid and Photodynamic Therapy (ALA-PDT) for Treatment of Vitiligo.

Combined therapy of 5-aminolevulinic acid photodynamic therapy and intense pulsed light for rosacea